Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical and laboratory studies of the novel cyclin-dependent kinase inhibitor dinaciclib (SCH 727965) in acute leukemias
Authors
Keywords
Dinaciclib, Acute leukemia, Cyclin-dependent kinase, CDK inhibitor, Mcl-1
Journal
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 72, Issue 4, Pages 897-908
Publisher
Springer Nature
Online
2013-08-14
DOI
10.1007/s00280-013-2249-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies
- (2012) Da Zhang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Outcome of patients with relapsed or refractory chronic lymphocytic leukemia treated with flavopiridol: impact of genetic features
- (2012) J A Woyach et al. LEUKEMIA
- Initial testing (stage 1) of the cyclin dependent kinase inhibitor SCH 727965 (dinaciclib) by the pediatric preclinical testing program
- (2012) Richard Gorlick et al. PEDIATRIC BLOOD & CANCER
- Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias
- (2011) J. E. Karp et al. BLOOD
- Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models
- (2011) Georg Feldmann et al. CANCER BIOLOGY & THERAPY
- A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected hepatotoxicity in patients with solid tumors
- (2011) Christophe Massard et al. CELL CYCLE
- The CDK inhibitors in cancer research and therapy
- (2011) Jonas Cicenas et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol
- (2011) K A Blum et al. LEUKEMIA
- The Cyclin-Dependent Kinase Inhibitor SCH 727965 (Dinacliclib) Induces the Apoptosis of Osteosarcoma Cells
- (2011) W. Fu et al. MOLECULAR CANCER THERAPEUTICS
- Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias
- (2010) W. Blum et al. HAEMATOLOGICA
- Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor
- (2010) David Parry et al. MOLECULAR CANCER THERAPEUTICS
- Phase II Study of Flavopiridol in Relapsed Chronic Lymphocytic Leukemia Demonstrating High Response Rates in Genetically High-Risk Disease
- (2009) Thomas S. Lin et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
- (2009) Judith E. Karp et al. LEUKEMIA RESEARCH
- Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
- (2008) M. A. Phelps et al. BLOOD
- An Unusual Member of the Cdk Family: Cdk5
- (2008) Fatema A. Dhariwala et al. CELLULAR AND MOLECULAR NEUROBIOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More